Risks in Finding Doses for a New Drug
The New England Journal of Statistics in Data Science · 01.01.2025 · 212-221
DOI: 10.51387/25-nejsds081 ↗Kurz gefasst
Fachartikel in der Zeitschrift The New England Journal of Statistics in Data Science, online erschienen am 06.01.2026. Verfasst von Naitee Ting. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The biggest risk in new drug development is either unaware of, or under-estimate the potential risks in designing clinical trials. Among all challenges in drug development, the most critical one is about finding the appropriate dose(s) for the study drug in treating patients. Designing dose finding clinical trials involves in many potential risks. In practice, most of the expensive failures in drug development originated not from “We did not know”, rather, the mistake is “We thought we knew”. In other words, greatest risks came from lack of awareness of underlying assumptions. This manuscript attempts to discuss some of these risks and make recommendations to reduce risks in the design of dose finding clinical trials. This is not a complete list of risks, but it is only starting the discussion.
Zitieren
APA
Ting, N. (2025). Risks in Finding Doses for a New Drug. The New England Journal of Statistics in Data Science, 212-221. https://doi.org/10.51387/25-nejsds081
Vancouver
Ting N. Risks in Finding Doses for a New Drug. The New England Journal of Statistics in Data Science. 2025:212-221. doi:10.51387/25-nejsds081
BibTeX
@article{Ting2025,
author = {Ting, Naitee},
title = {Risks in Finding Doses for a New Drug},
journal = {The New England Journal of Statistics in Data Science},
year = {2025},
pages = {212--221},
doi = {10.51387/25-nejsds081}
}
EUVIMED